AngioDynamics Q1 2025 Earnings Report
Key Takeaways
AngioDynamics reported a 1.1% increase in net sales compared to the prior-year quarter, with Med Tech net sales up by 8.7%. The company's GAAP loss per share was $0.31, and the adjusted loss per share was $0.11. The company submitted for FDA 510(k) clearance for Prostate Tissue indication for NanoKnife, received CE Mark Approval in Europe for the Auryon System, and initiated RECOVER-AV Clinical Trial in Europe for AlphaVac.
Net sales increased by 1.1% compared to the prior-year quarter.
Med Tech net sales increased by 8.7% year-over-year.
Auryon and AlphaVac both delivered over 20% growth in the quarter.
Submitted for FDA 510(k) clearance for Prostate Tissue indication for NanoKnife and Received CE Mark Approval in Europe for the Auryon System.
AngioDynamics
AngioDynamics
AngioDynamics Revenue by Segment
AngioDynamics Revenue by Geographic Location
Forward Guidance
For fiscal year 2025, AngioDynamics expects net sales in the range of $282 to $288 million, Med Tech net sales are expected to grow in the range of 10% to 12%, Med Device net sales are expected to grow in the range of 1% to 3%, gross margin to be approximately 52% to 53%, adjusted EBITDA loss of $2.5 million to $0, and adjusted loss per share in the range of $0.38 to $0.42.
Positive Outlook
- Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% – 6.4% over fiscal 2024 pro forma revenue of $270.7 million
- Med Tech net sales are expected to grow in the range of 10% to 12%
- Med Device net sales are expected to grow in the range of 1% to 3%
- Gross margin to be approximately 52% to 53%
- Adjusted EBITDA loss of $2.5 million to $0, compared to a pro forma adjusted EBITDA loss of $3.2 million in fiscal year 2024
Challenges Ahead
- Adjusted loss per share in the range of $0.38 to $0.42, compared to pro forma adjusted loss per share of $0.45 in fiscal year 2024
Revenue & Expenses
Visualization of income flow from segment revenue to net income